Glaukos Corporation has raised its net sales guidance for 2025, now expecting revenue in the range of $490 million to $495 million, up from its previous estimate of $480 million to $486 million. The company also introduced its preliminary net sales outlook for 2026, forecasting sales between $600 million and $620 million. In the third quarter of 2025, Glaukos reported record net sales of $133.5 million, marking a 38% year-over-year increase. U.S. glaucoma sales saw particularly strong growth, rising 57% year-over-year to $80.8 million. The company achieved a gross margin of approximately 78% and a non-GAAP gross margin of about 84% for the quarter.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251029588082) on October 29, 2025, and is solely responsible for the information contained therein.